• AstraZeneca’s Fasenra Fails to Reduce COPD Exacerbations, Phase 3 Trial Shows
  • #ATS2018 – Potential COPD Treatment, RPL554, Seen to Aid Bronchodilation in Combo with Spiriva
  • Strategy to Fight COPD-related Lung Inflammation Could Help Millions, Researchers Contend
  • Blocking Cholesterol Derivative May Offer Way to Treat COPD, Study Suggests
  • FDA Extends Trelegy Ellipta as Maintenance Treatment to Broader Group of COPD Patients
  • Doctors and Patients View Inhaler Devices as Less Important than COPD Medication, Survey Shows
  • Trelegy Ellipta Reduces COPD Exacerbations, Improves Lung Function and Quality of Life, Trial Shows
  • ATS Foundation/Insmed Announces $50K Research Award in NTM Lung Disease
  • 100 Million Chinese Adults Have COPD, but Most Are Unaware of It, Study Reports
  • Tai Chi Improves Respiratory Function in Patients with COPD, Study Shows
  • Treatment with Spiolto Respimat Reduces Rate of COPD Flare-ups Compared to Spiriva Respimat, Study Shows
  • Arch Biopartners’ Therapy Candidate AB569 Receives US Patent for Treatment of Chronic Lung Infections